INTRODUCTION
Chronic nonhealing venous leg ulcers (VLUs) continue to be a cause of substantial morbidity, straining health care budgets and negatively affecting quality of life. More than 70% of VLUs fail to heal with standard of care compression therapy and have high recurrence rates, posing additional burden to wound care professionals. The chronicity, frequent relapses, and associated complications of nonhealing VLUs heavily affect patients' quality of life and increase health care expenditures for millions of people worldwide.
Deciphering the network of deregulated wound healing processes present in chronic VLUs is challenging, and many therapies showing promise in the laboratory and in initial clinical trials have failed to improve clinical outcomes. The histologic hallmark of chronic VLUs is a hyperproliferative wound edge, which is characterized by nonmigratory keratinocytes, decreased angiogenesis, an increase in proteases, increased bacterial colonization and/or infection, and inflammatory infiltrates (1, 2) . We have shown that the nonhealing VLU edge displays loss of genes controlling the fate of local stem cells and their niche, as well as aberrant activation of b-catenin and c-myc (2, 3) . Moreover, genomic profiling of VLUs has revealed deregulation of epidermal activation and differentiation, including attenuation of epidermal growth factor (EGF) and transforming growth factor-b (TGF-b) receptor signaling (4) . However, the molecular pathophysiology of VLUs has not yet been fully elucidated, which has slowed the development and validation of targeted therapies (5) . There is an urgent need for therapeutic approaches that would target multiple aberrantly regulated cellular processes simultaneously, successfully converting the nonhealing VLU to a healing wound phenotype. Furthermore, enhanced understanding of the molecular pathophysiology of chronic VLUs is critical in identifying relevant clinical trial end points that can be used to evaluate new treatments, paving the way for delivery of maximally efficacious therapies to VLU patients.
A U.S. Food and Drug Administration (FDA)-approved bioengineered bilayered living cellular construct (BLCC) has demonstrated efficacy in promoting healing of chronic ulcers (6, 7) . The BLCC skin substitute consists of human foreskin-derived neonatal fibroblasts in a bovine type I collagen matrix below a layer of human foreskin-derived neonatal epidermal keratinocytes. The BLCC has been suggested to interact with the surrounding environment to promote wound healing. In vitro, the BLCC produces growth factors and cytokines that are indispensable for a successful wound healing process (8) (9) (10) , but the precise in vivo mechanism of action is unknown. To this end, we designed a randomized controlled postmarketing clinical trial to investigate the effects of a commercially available BLCC (Apligraf, Organogenesis Inc.) on gene expression in chronic VLUs. We analyzed human wound edge biopsies obtained from nonhealing VLUs at baseline and 1 week after BLCC treatment. We hypothesized that treatment with the BLCC might activate responsiveness to cellular signals similar to those that facilitate successful healing of acute wounds, thus changing a nonhealing to a healing phenotype.
RESULTS

Randomized controlled trial of the nonhealing VLU response to BLCC treatment
The study design and participant information for clinical trial no. NCT01327937 is summarized in Fig. 1 and described further in the Supplementary Materials and Methods. Briefly, potential study participants with VLUs (n = 30) were treated with the standard of care compression therapy for 4 weeks. Patients with nonhealing VLUs, defined as those who did not have a 40% reduction in ulcer size with compression therapy over this time period, were enrolled and randomly assigned to receive either ongoing standard of care treatment with compression dressings (control group, n = 9) or up to five weekly BLCC applications in addition to the standard of care (treatment group, n = 15). Biopsies from the wound edge were obtained at baseline (week 0) and at week 1 for all ulcers, capturing the interval of the first week after study allocation, and ulcer size was monitored over time. At this time point, insufficient RNA quality or quantity was one of the exclusion criteria. Of the patients from whom tissue specimens were obtained, about one-third yielded sufficient high-quality RNA from paired week 0/week 1 biopsies to enable microarray analysis ( Fig. 1 and tables S1 and S2).
Immune signals and growth stimuli provided to chronic VLUs by the BLCC skin substitute The primary outcome measure of our clinical trial was to evaluate changes in the gene expression in wound biopsies from subjects with nonhealing VLUs 1 week after BLCC application compared to the gene expression in wound biopsies from subjects with nonhealing VLUs 1 week after standard of care. To this end, we examined paired microarray profiles of biopsies from the patients with nonhealing VLUs before and after a single application of the BLCC (week 0 to week 1) and compared those to biopsies from the VLU controls receiving standard of care compression therapy (Fig.  1) . The peak of the BLCCmediated effect was expected in the first week of treatment, based on dosing in previous clinical trials (7, 8) . To exclude the possibility that BLCC (as opposed to wound tissue) was evaluated, DNA genotypes from week 1 biopsies were examined and compared to cellular genotypes of the BLCC used, to ensure that no cells from the BLCC were detectable in the biopsy specimens at the 1-week time point. We found 559 microarray probes (corresponding to 424 unique genes) significantly differentially expressed between week 0 and week 1 after BLCC treatment, compared to differential expression in control biopsies, which showed a change in only 92 probes (70 genes) (paired t test, P < 0.05; fold change, >1.5). There were five genes Ulcer size at screening was determined at the time of enrollment (study week −4), whereas size at allocation was determined at week 0, when patients were randomly assigned to BLCC or control treatment groups. Asterisk (*) indicates that the sample biomaterial was of insufficient quality for sensitive microarray analysis but was available for validation of study findings.
that overlapped between BLCC-treated and control biopsies (Fig. 2A  and table S3) .
Although some variability in gene expression among individual study subjects was evident, a clear BLCC-specific consensus transcriptional signature emerged ( fig. S1 ). Gene ontology analysis of differentially expressed entities after BLCC application highlighted a strong enrichment in immune system biological processes, with 18.1% (101 of 559) of the modulated genes related to the immune response (P = 2.83 × 10 −26 ) (Fig. 2B) . The highly enriched biological processes also included "regulation of response to wounding," as well as "epithelium development," consistent with the demonstrated clinical role for the BLCC in accelerating wound healing.
Ingenuity Pathway Analysis (IPA) of the differentially expressed genes after BLCC treatment identified multiple enriched pathways ( Fig. 2C and table S4 ), all of which are related to various aspects of the innate and adaptive immune response. In contrast, in the standard of care VLUs, no significantly enriched pathways were identified using this approach. Using published algorithms (11), IPA Core Analysis generated predicted networks connecting upstream regulators to downstream biological processes that were significantly enriched among the BLCC-stimulated genes. One such network is shown in Fig. 2D , in which the upstream regulator interleukin1b (IL1b) induced a set of chemokines, which was significantly up-regulated after BLCC treatment, to increase chemotaxis, an enriched and activated biological process (Fig. 2B) . These pathway and network data provide initial support for the hypothesis that BLCC application introduces an alternate inflammatory response distinct from chronic inflammatory infiltrates typically found in nonhealing VLUs (12) .
IPA analysis also predicted multiple upstream regulators whose targets were enriched among BLCC-modulated genes, including such key wound healing factors as TGFb, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and plateletderived growth factor (PDGF) (Fig. 2E) . Moreover, the directionality of downstream gene expression (that is, induction versus inhibition) supported active signaling states of these growth factors (table S5 and fig. S2 ).
Generation of acute and chronic wound reference gene expression profiles We hypothesized that the inflammation triggered by BLCC application was similar to that invoked during the acute wound healing response. To explore this possibility, we needed to differentiate the inflammation during acute wound healing, which leads to successful wound closure, from the chronic inflammation present in the background of nonhealing VLUs. To do so, we generated three reference gene expression profiles comparing intact skin, acute wounds at day 3 after wounding, and chronic VLUs (Fig. 3A and table S7). We used these reference gene expression profiles to explore possible mechanisms through which application of BLCC might uniquely shift chronic nonhealing VLUs to an acute wound healinglike phenotype.
To obtain an acute wound healing profile that could be coordinately analyzed head to head with our chronic VLU profiles, we used the raw in vivo full-thickness acute wound microarray data previously generated from human skin graft donor site wounds [Gene Expression Omnibus (GEO) accession no. GSE28914 (13) ]. We downloaded paired data from six patients, comparing intact versus healing skin at day 3 after wounding (13) , to capture the early response and inflammatory phase of acute wound healing (acute versus intact; Fig. 3A and tables S6 and S7). A reference expression profile of the prototypic nonhealing chronic VLUs was obtained from the pretreatment (week 0) biopsies of three patients with VLUs who displayed poorest healing trajectories during the 4-week screening period before randomization ( fig. S3 ; patients C2, C3, and T6), as compared with biopsies of healthy (intact and unwounded) skin (chronic versus intact; Fig. 3A and tables S6 and S7). Finally, we compared the acute wound profiles to transcriptional profiles of the baseline chronic VLUs to enable discrimination of the acute response from the background of chronic VLU inflammation (acute versus chronic; Fig. 3A and table S6). The three reference profiles contained distinct and overlapping genes (Fig. 3A) .
We used these reference profiles to propose the following mechanisms for BLCC effects. For genes modulated in both acute and chronic wounds, changes may occur in expression but in opposite directions when compared to intact skin, but BLCC treatment might revert the expression in VLUs toward the acute wound phenotype (Fig. 3B , "a"). For genes with consistently altered expression in both acute wounds and chronic VLUs, but pathologically over-or underexpressed in VLUs, the BLCC may normalize this perturbed gene expression back to expression levels observed in acute healing wounds ( Fig. 3B , "b"). For genes modulated during acute wound healing, but not in chronic VLUs, the BLCC may regulate the response in the direction consistent with acute wound levels, which are associated with a beneficial healing outcome (Fig. 3B , "c").
BLCC reversal of gene dysregulation in nonhealing chronic
VLUs toward an acute wound healing phenotype We proceeded to examine the BLCC and control gene expression profiles (week 1 versus week 0; table S3) for evidence of the proposed mechanisms in Fig. 3B . We identified caspase-14 (CASP14) as a BLCC-modulated gene representing model a in Fig. 3B . CASP14 is a nonapoptotic caspase with a critical role in the terminal differentiation of keratinocytes (14) . As expected, its expression was lower in acutely healing wounds and, consistent with previous reports (4), was higher in nonhealing chronic VLUs (Fig. 4A ). CASP14 transcript levels were down-regulated in VLUs after BLCC treatment, adopting the direction of acutely healing wounds (Fig. 4A ).
Model b in Fig. 3B was represented by the expression of integral membrane protein 2A (ITM2A) and type 2 thyroid deiodinase (DIO2) (Fig. 4 , B and C). ITM2A is an integral transmembrane protein that is variably expressed in T cell lineage hematopoietic cells, with high expression in select subsets of activated T cells and lower expression in stimulated regulatory T cells (15, 16) . BLCC application induced expression of ITM2A in the chronic VLUs to an expression level consistent with an acutely healing wound. DIO2 was induced during acute wounding and even further overexpressed in chronic nonhealing VLUs (Fig. 4C) . DIO2 catalyzes the conversion of thyroid hormone to its active form (T 3 ) and functions as the key regulator of thyroid hormone action on target tissues, including the skin (17) . Thyroid hormone broadly influences epidermal development and function and has a demonstrated role in wound healing (18) . DIO2 expression in BLCC-treated VLUs was similar to that in healing acute wounds (Fig. 4C ). ITM2A and DIO2 expressions were unchanged in the VLUs from control patients receiving the standard of care; none of the genes expressed in the group receiving compression therapy alone showed the expression pattern in model b of Fig. 3B (table S3) .
We identified multiple up-and down-regulated genes ( (PCA) demonstrated a shift in BLCC-treated VLUs, but not in control VLUs, toward a gene expression profile-consistent with acute wounds during the inflammatory wound healing phase (day 3) (Fig. 4E) . Moreover, when plotted against each other, changes in gene expression in acute wounds correlated significantly with changes in gene expression in BLCC-treated VLUs (Fig. 4F) .
Recapitulation of biological processes of acute wound healing by BLCC treatment Pathway analysis also supported the global hypothesis that BLCC treatment, in contrast to standard of care compression therapy alone, reverted the chronic nonhealing VLUs to an acute wound healing phenotype. We performed IPA on the reference gene profiles established in Fig. 3A and compared them with biological pathways enriched in BLCC-and control-treated VLUs (week 1 versus week 0) (see tables S3 and S7). Although a small number of genes were modulated in both BLCC-and control-treated VLUs, acute wound healing biologic pathways including innate and adaptive immunity and their interaction were enriched exclusively in acute and BLCC-treated VLUs ( Fig. 5A and table S8 ). Biological processes of B cell proliferation, antibody production, calcium mobilization, and T cell differentiation, activation, migration, and signaling were present in BLCC-treated wounds but absent in chronic VLUs at baseline or after compression treatment ( Fig. 5B and table S9 ).
BLCC treatment-induced acute inflammatory wound healing in chronic VLUs
To validate our microarray findings, we used Ingenuity Knowledge Base to identify a literature-supported network of genes and biological processes enriched in acute healing and BLCC-treated wounds but not chronic VLUs at baseline or after standard of care treatment (Fig. 6A ). An expanded pool of biopsies from BLCC-treated (n = 8) and control-treated (n = 4) VLUs was used to validate the expression of IL1b, CXCL1, CXCL2, and CXCL3 using quantitative polymerase chain reaction (qPCR) (Fig. 6B) . We used a well-characterized ex vivo model of acute wound healing (19) using healthy human skin samples (n = 2) to confirm the induction of all four genes during the acute wounding response (Fig. 6C and fig. S4 ). Qualitative immunofluorescence analysis of protein tyrosine phosphatase receptor type C (PTPRC), which encodes the CD45 receptor expressed on the surfaces of leukocytes, identified an increased dermal infiltrate of CD45 + cells in BLCC-treated tissue samples (Fig. 6D) . We confirmed that BLCC treatment induced Toll-like receptor 4 (TLR4) expression in the upper spinous and granular layers of the epidermis (Fig. 6E) . TLR4 functions in both innate and adaptive immunity and is an important player in the inflammatory phase of early wound healing (20) .
Attenuated Wnt/b-catenin signaling in healing BLCC-treated VLUs
The BLCC skin substitute has demonstrated efficacy in healing chronic ulcers in conjunction with standard therapy (6, 7), but VLUs that do not respond to initial applications of BLCC are unlikely to derive additional clinical benefit from repeated BLCC treatments (21) . To determine whether gene expression could be retrospectively correlated with a successful 4-week healing trajectory, we performed regression analysis on the healing curves of the control-and BLCC-treated VLUs from week 0 through week 4 (Fig. 7) . We identified changes in gene expression from week 0 to week 1 in the BLCC-treated VLUs that correlated with the trajectory slope of the "healers" but not with the slope of the "nonhealers" or controls receiving compression therapy alone (table S10). One of these genes was CSNK2A2, a casein kinase with an essential role in Wnt/b-catenin signaling (22) . BLCC Fig. 2A were explored in the context of the models proposed in Fig. 2B by comparing reference profiles of intact unwounded skin, healing acute wounds at day 3 after injury, and the nonhealing edge of chronic VLUs to pairs of nonhealing VLUs before and after BLCC treatment. Data are represented as box-and-whisker plots of microarray probe expression intensities in the unwounded skin ("Intact," n = 6), healing acute wounds ("Acute," n = 6), nonhealing chronic VLUs ("Chronic," n = 3), as well as six pairs of BLCC-treated VLUs ("W0" and "W1"). (A) Model "a": CASP14 expression in intact, acute, and chronic reference samples compared to BLCC-treated VLUs at W0 and W1. (B and C) Model "b": ITM2A and DIO2 expression in intact, acute, and chronic reference samples compared to BLCC-treated VLUs at W0 and W1. P values were determined by two-tailed paired t test (acute versus intact; BLCC W1 versus W0) or two-tailed moderated t test (acute versus chronic; BLCC W1 versus acute). (D and E) Model "c": Fourcomponent PCA of 168 microarray probes common to healing acute wounds and chronic VLUs after BLCC (shaded in gray); plot of components 1 and 2 comprise over 70% of the variation. Arrow represents the trend toward acute wound expression in 1 + PCA components for pairs of BLCC-treated VLUs (BLCC week 0 to 1), which is absent in control-treated pairs (dotted rectangles). (F) Plot of changes in the gene expression for BLCC-treated VLUs (fold change; W0 to W1) and changes in the gene expression between acute wounds and intact skin as determined by Spearman's nonparametric rank order correlation (two-tailed P < 0.0001).
treatment decreased CSNK2A2 expression in VLUs, and the magnitude of down-regulation correlated with the healing extent in the healers [R 2 = 0.9980 (correlation); P = 0.02] but not in nonhealers and/or control VLUs (Fig. 7A) . Reduced expression of CSNK2A2 is a shared feature of BLCC-healing VLUs and acute wound healing because CSNK2A2 expression decreased in vivo by about threefold at 72 hours after wounding (Fig. 7B and table S7 , acute versus intact). Furthermore, WNT3, which regulates CSNK2A2 activity (22) , decreased in BLCC-treated chronic VLUs and in in vivo and ex vivo models of acute wound healing (Fig. 7C) . Finally, although immunofluorescence of phosphorylated b-catenin in nonhealing VLUs confirmed previously described intense nuclear staining in wound edge keratinocytes (2), nuclear b-catenin was absent in portions of BLCC-treated healing VLUs (Fig. 7D) .
DISCUSSION
Our clinical trial was designed to understand the mechanisms of action of an FDA-approved skin substitute that has already demonstrated clinical efficacy in healing chronic ulcers (6) . We found that BLCC application induces genes and processes of acute inflammatory healing, activates keratinocytes, and diminishes Wnt/b-catenin signaling, thus recapitulating features of the acute wound phenotype. Our data therefore suggest that therapeutic approaches that can successfully activate an acute wound healing response have the greatest likelihood of being efficacious in the clinical setting. Hence, our findings provide representative testable genomic and molecular end points that can be incorporated into the design of the future clinical trials testing the efficacy of VLU therapies.
Our data demonstrate that BLCC application triggers an inflammatory response that is distinct from the chronic inflammation present in nonhealing VLUs at baseline. It is unlikely that we are capturing acute rejection of the allogeneic cells of the BLCC, that is, graft-versushost response, for several reasons. First, well-documented clinical signs of rejection, such as pain, erythema, and necrosis, are absent from both acute and chronic wounds that have been treated with BLCC (6, 23) . Second, the BLCC does not contain resident skin antigenproducing cells, such as Langerhans cells or melanocytes, and keratinocytes and fibroblasts do not express class II human leukocyte antigens (HLAs) or other immune costimulatory molecules (6) . Third, antibodies signifying a BLCC-specific immune rejection (for example, anti-HLA type I BLCC alloantigens) were not detectable in VLU patients treated with BLCC (6) .
Rather than reflecting a rejection response, comparison of the BLCC gene expression profile to in vivo acute wound profiles illustrated that this BLCC-invoked inflammation recapitulated features of the inflammatory phase of acute wound healing, which is an essential stage of successful wound closure. We demonstrated this at the level of individual genes as well as at the level of coordinately enriched pathways and biologic processes in acute wounds and BLCC-treated chronic ulcers. Their expression in healing versus nonhealing wounds might thus reflect fine-tuning of the adaptive immune response. Moreover, our data may indicate that prolonged inflammation present in nonhealing VLUs does not facilitate progression of healing found in acute wounds. Further, our data support the hypothesis that BLCC application reverts this suboptimal inflammation to activate acute inflammatory signaling similar to that seen in an acute wound healing environment.
The gene expression changes in paired VLU biopsies before and after treatment illustrated that BLCC triggered therapeutic reprogramming, reversing the nonhealing phenotype and activating prohealing pathways. These changes were not present in the control VLU group treated with standard of care compression therapy alone, indicating BLCC-specific effects. The only exception was RARRES1 (retinoic acid receptor responder 1), an acute wound healing gene that was upregulated in both BLCC and control groups 1 week after treatment, perhaps reflecting continued optimal standard of care compression therapy, which both groups received, rather than a BLCC-unique mechanism. There are three possible mechanisms by which BLCCinitiated activation of healing may occur: (i) as demonstrated in vitro (8) (9) (10) , the BLCC secretes growth factors and cytokines common to the prohealing pathways; (ii) the BLCC stimulates patients' VLU cells to activate prohealing signaling pathways; or (iii) the BLCC both secretes growth factors and activates prohealing signaling pathways within the VLUs. Although it is not possible to test which of these three mechanisms occurred in our study, our gene expression data confirm that these important wound healing signaling pathways are activated and successfully executed in VLUs only upon BLCC and not standard compression treatment. Similarly, our findings do not pinpoint the exact cellular source(s) of the acute wound healing signals captured by our post-BLCC microarrays because there are several cell types that could contribute to the gene expression changes detected in the VLU edge after BLCC. However, because no BLCC DNA material was present in the VLUs after 1 week of treatment, our data indicate that the resident chronic VLU cells altered their transcriptomes in response to BLCC application.
Our study design was limited by the lack of repeated sampling and profiling of BLCC-treated VLUs at later time points. However, consistent with previous reports (24), we note again that no detectable BLCC cellular DNA remained in any of the VLU edge biopsies after 1 week of treatment. This observation implies that any direct BLCC-triggered effects are more likely to be detected within the initial week of treatment, which was the interval captured by our study, rather than at later time points. Given that original clinical trials of the BLCC's efficacy in VLUs only demonstrated a healing response months (rather than weeks) after treatment (6), the BLCC's early in vivo disappearance suggests that its initial therapeutic activity must be of sufficient intensity to effect sustained changes in the resident cells of the chronic wound, which then go on to gradually orchestrate successful wound closure.
The drawbacks of our study highlight a question that is of great importance to the field of chronic wound healing: should one perform in vivo "mechanism of action" studies in humans knowing that direct demonstration of causality cannot be attributed to anything more precise than the tissue response to the presence or absence of a particular therapeutic intervention? More to the point, the field of chronic wound healing is challenged by a lack of validated preclinical models, a factor that severely impedes translation of therapies to clinical practice. Given this reality, we believe that there are two choices: to continue using products without attempting to elucidate their mechanisms of action in this complex multifactorial disease and thus impede development of second-generation products for chronic wounds, or to accept the limitations of more descriptive, less mechanistic approaches to deciphering how patients' tissues respond to therapies to gain potential valuable clinical insights. We argue that our clinical trial findings have direct clinical relevance. We were able to provide initial validation for specific biologic processes through which placement of the BLCC converts chronic nonhealing VLUs into an acute wound healing phenotype. These biologic processes may serve as specific targets and testable end points in the design and testing of future VLU therapies, which are sorely needed in the clinical setting. Moreover, we identified early changes in gene expression that, upon further validation in larger patient groups, may be predictive of healing outcomes after BLCC application. These early indicator genes could help identify subsets of patients with chronic wounds who are most likely to derive clinical benefit from BLCC therapy. For instance, Wnt/b-catenin signaling is highly dysregulated in chronic VLUs (2, 3), and we found that expression of the Wnt family member CSNK2A2 correlated with healing in BLCC-treated ulcers. CSNK2A2 might thus serve as a molecular marker that indicates commencement of healing with an initial application of the BLCC, warranting repeated treatments.
Fifteen years after initial pivotal clinical trials demonstrated efficacy of BLCC in healing chronic VLUs, data from our study provide new insights into how and why this occurs. We believe that similar studies can be integrated into clinical trials, providing new foundations upon which existing and novel diagnostic and therapeutic approaches for chronic wound healing can be examined. This has the potential to positively affect the lives of patients suffering from nonhealing VLUs.
MATERIALS AND METHODS
Study design
Study participants (ClinicalTrial.gov; NCT01327937) were recruited from patients presenting to the wound clinic at the University of Miami (Miami, FL) with VLUs. Written informed consent was obtained from all subjects enrolled in the clinical trial, and the study protocol and informed consent were approved by the Institutional Review Board (IRB) of the University of Miami. All subjects (n = 30), from screening (day −28) through day 0 visit, received the standard of care, including a dressing regimen of a foam dressing and a four-layered compression bandage system. Participants with noninfected target ulcers of >5 cm 2 that had not reduced in area by >40% during the 4-week screening period were randomized to either the control group receiving standard of care compression therapy (foam dressing plus four-layered compression bandage system, changed weekly by the investigator) (n = 9) or to the treatment group receiving weekly BLCC applications (Apligraf, Organogenesis Inc.), along with standard of care compression therapy (n = 15). Before all applications, the BLCC was fenestrated in a standardized manner using a #11 blade with six fenestrations per 44 cm 2 . Skin biopsy specimens were obtained from the nonhealing edges of VLUs at the time of randomization (week 0) as well as 1 week later (week 1). Specimens were clinically designated by a physician as the most proximal skin edge to the ulcer bed. All patients were debrided, and local lidocaine injection was used for anesthesia. After week 5, all patients were monitored in the wound clinic for 12 weeks or until wound closure was achieved. In addition, to confirm the acute wound profile, ex vivo human skin experiments were performed on discarded human skin tissue obtained from voluntary surgeries (n = 2 donors) at the University of Miami Hospital and were found to be exempt under 45 CFR46.101.2 by the IRB at the University Of Miami Miller School Of Medicine. See the Supplementary Materials and Methods for full clinical study protocol and ex vivo experiment details.
Sample processing Skin biopsies were processed as follows: samples were (i) embedded in OCT compound (Fisher Scientific), (ii) stored in formalin for paraffin embedding, and/or (iii) stored in RNA later or homogenized in TRIzol (Ambion/Applied Biosystems) or snap-frozen for subsequent RNA/ protein isolation. Tissue morphology was evaluated using hematoxylin and eosin staining. Genotyping of a portion of each week 1 biopsy in the BLCC treatment group was performed by an outside laboratory (Esoterix Clinical Trials Services).
VLU morphology assessment
Biopsies obtained from VLU wound edges were formalin-fixed and paraffin-embedded. Sections (5 mm thick) were stained using hematoxylin and eosin following standard protocol and assessed for the presence of epidermis and dermis, thus confirming characteristic VLUs morphology as previously described (2).
Gene expression microarrays
Microarray experiments were performed at the University of Miami's Genomic Facility Core. RNA was amplified, fragmented, and hybridized to arrays using the GeneChip 3′ IVT Express kits following the manufacturer's protocol (Affymetrix). Total RNA (100 ng) was used as input for the Ambion WT Expression Kit to produce labeled single-stranded complementary DNA (cDNA) according to the manufacturer's instructions. Labeled products were hybridized to GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix). The staining, washing, and scanning of the arrays were carried out using Fluidics 450 station, GeneChip Operating Software, and GeneChip Scanner 3000 7G (Affymetrix). For quality control, Bioanalyzer analysis after the generation of complementary RNA, cDNA, and fragmentation was carried out using the 6000 Nano Kit (Agilent). Microarray data were analyzed as described in the Supplementary Materials and Methods.
Pathway analysis
Gene set enrichment analysis was performed using the Gene Ontology tool contained within the GeneSpring 13.0 Suite. Further pathway analysis and downstream target/functional predictions were performed using IPA (Qiagen; www.ingenuity.com). Microarray probes were mapped to the corresponding genes using the Ingenuity software; if multiple probes mapped to the same gene, the gene was used only once in enrichment calculations. Counts and lists of genes used as inputs for pathway analysis are found in tables S3 and S6. Statistical tools within the IPA software package used Fisher's exact test to detect the reported significantly enriched pathways, biologic processes, and upstream regulators; in all cases, enrichment P values were Benjamini-Hochberg-corrected for multiple testing.
Ex vivo acute wound model Skin from two independent healthy donors was wounded and processed as described (19) . RNA and formalin-fixed/paraffin-embedded sections were used for qPCR analyses. Refer to the Supplementary Materials and Methods for full details of experimental design and donor demographics.
Statistical analysis
Statistics for microarray data were performed as described in the Supplementary Materials and Methods. For qPCR validation studies, technical triplicates were included and groups were compared using two-sided paired t test. Correlation of nonparametric data was assessed using Spearman's test. Gene ontology enrichment P values were calculated within the GeneSpring 13.0 software package, which uses the Broad Institute GSEA algorithms. Pathway enrichment statistics were calculated within the Ingenuity software package using Fisher's exact test with Benjamini-Hochberg correction for multiple testing. Growth factor upstream regulator overlap P values were similarly calculated within IPA using Fisher's exact test. Two-sided testing was performed with a < 0.05 for all reported analyses, as specified in the corresponding figure legends.
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